Integrated BioPharma Reports $1.4 Million Quarterly Net Loss

Integrated BioPharma (INBP) reported revenue of $9.8 million for the quarter ended June 30, 2026, down 31.0% from $14.2 million a year earlier. The company recorded a net loss of $1.4 million, or $0.04 per basic and diluted share, compared with a net loss of $0.2 million, or $0.01 per share, in the prior-year quarter.

For the fiscal year ended June 30, 2026, the release said revenue was $43.9 million, down 19.3% from $54.4 million in fiscal 2025. It reported a fiscal-year net loss of $2.8 million, or $0.09 per basic and diluted share, versus net income of $0.8 million, or $0.03 per share, a year earlier.

• Quarterly operating loss was $0.9 million, compared with operating income of approximately $0.6 million a year earlier.
• Fiscal-year operating loss was approximately $2.7 million, compared with operating income of $2.0 million in fiscal 2025.
• The company said its two largest contract manufacturing customers represented approximately 90% of fiscal 2026 total revenue.